Reaction

Rhonchi reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,368 reports · 73 co-occurring drugs

As of the last recalculation, Rhonchi appears in 1,368 FAERS reports alongside 73 co-occurring drug terms. The strongest observed disproportionality signal is CICLESONIDE (PRR 124.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ciclesonide	103	124.3	125.3
Theophylline Anhydrous	71	91.8	92.4
Theophylline	64	88.8	89.3
Fluticasone Furoate	43	55.7	55.9
Ipratropium Bromide	117	54.5	54.6
Fluticasone Propionate And Salmeterol Xinafoate	112	30.8	30.9
Esomeprazole Magnesium Capsule, Delayed Release	27	28.9	28.9
Esomeprazole Magnesium Delayed Release Capsules	27	28.9	28.9
Esomeprazole Magnesium Dihydrate	27	28.7	28.8
Montelukast Sodium	183	26.2	26.3
Mercaptopurine	28	25.1	25.1
Omalizumab	122	23.8	23.8
Valsartan Oral	75	22.2	22.2
Azithromycin Dihydrate	80	22.0	22.0
Fluticasone Furoate And Vilanterol Trifenatate	47	20.6	20.6
Captopril	12	19.1	19.2
Digoxin	83	18.7	18.7
Tobramycin Sulfate	15	18.6	18.6
Valsartan And Hydrochlorothiazide	16	18.1	18.1
Budesonide And Formoterol Fumarate Dihydrate	106	17.9	17.9
Guaifenesin	33	16.8	16.9
Tobramycin	26	16.7	16.8
Albuterol	121	16.7	16.7
Tobramycin Solution	13	16.6	16.6
Albuterol Sulfate	265	16.6	16.6
0Xygen	51	16.3	16.3
Oxygen	51	16.3	16.3
Phytonadione	9	16.2	16.3
Quinine	9	16.1	16.1
Mepolizumab	49	15.5	15.5
Cetirizine Hydrochloride Allergy	30	15.4	15.4
Cetirizine Hydrochloride Tablets	30	15.4	15.4
Azithromycin	39	15.1	15.2
Azithromycin Monohydrate	39	14.6	14.6
Standardized Senna Concentrate	12	14.6	14.6
Diltiazem Hydrochloride	32	14.4	14.4
Nicotine Polacrilex Mini	14	14.3	14.3
Nicotine Polarilex	14	14.3	14.3
Naproxen Sodium, Dextromethorphan Hydrobromide, Guaifenesin	19	14.2	14.2
Naproxen Sodium, Pseudoephedrine Hydrochloride	19	14.2	14.2
Valsartan	91	14.0	14.1
Tiotropium Bromide	115	13.9	13.9
Montelukast	72	13.7	13.7
Tiotropium Bromide Inhalation Spray	10	13.7	13.7
Magnesium Hydroxide	12	13.7	13.7
Metolazone	10	13.6	13.6
Piperacillin Sodium And Tazobactam Sodium	17	13.3	13.3
Budesonide	49	13.1	13.1
Enalapril Maleate	21	13.1	13.1
Atropine	7	12.9	12.9
Meclizine Hcl 12.5Mg	11	12.4	12.4
Meclizine Hcl 25Mg	11	12.4	12.4
Meclizine Hcl 12.5 Mg	11	12.4	12.4
Meclizine Hcl 25 Mg	11	12.4	12.4
Docusate Sodium 100Mg	19	12.2	12.3
Paroxetine Hydrochloride	69	12.1	12.1
Amoxicillin And Clavulanate Potassium	21	11.9	11.9
Febuxostat	13	11.9	11.9
Dornase Alfa	15	11.8	11.8
Quinapril Hydrochloride	6	11.6	11.6
Benzonatate	12	11.1	11.1
Duloxetine	49	11.1	11.1
Amiodarone Hydrochloride	8	10.9	10.9
Eplerenone	9	10.8	10.8
Conjugated Estrogens	40	10.7	10.7
Estrogens, Conjugated	40	10.5	10.5
Umeclidinium	6	10.2	10.2
Palivizumab	9	9.0	9.0
Iohexol	4	7.4	7.4
Budesonide, Glycopyrrolate, And Formoterol Fumarate	5	7.3	7.3
Benralizumab	9	6.9	6.9
Nicotine Polacrilex	14	5.6	5.6
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	14	5.2	5.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.